Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$278.50+3.29 (+1.20%)
Delayed quote: Sep 3, 2026, 2:45 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Sep 3, 2026, 2:45 PM EDT
EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages 5.78% over 3 years and 4.20% over 5 years; the trailing 12 months came in at +12.29%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
Johnson & Johnson (JNJ)
EBITDA growth vs the same quarter one year earlier, last 40 quarters.
Reported quarterly EBITDA; no daily interpolation.
| Year | Start EBITDA | End EBITDA | Change | % Change |
|---|---|---|---|---|
| 2025 | $29.49B | $33.10B | +$3.61B | +12.25% |
| 2024 | $30.89B | $29.49B | −$1.41B | -4.55% |
| 2023 | $27.98B | $30.89B | +$2.91B | +10.41% |
| 2022 | $28.33B | $27.98B | −$350.00M | -1.24% |
| 2021 | $26.96B | $28.33B | +$1.37B | +5.08% |
| 2020 | $27.98B | $26.96B | −$1.01B | -3.63% |
| 2019 | $28.10B | $27.98B | −$125.00M | -0.44% |
| 2018 | $24.54B | $28.10B | +$3.56B | +14.53% |
| 2017 | $24.64B | $24.54B | −$106.00M | -0.43% |
| 2016 | $22.04B | $24.64B | +$2.61B | +11.84% |
| 2015 | $25.03B | $22.04B | −$3.00B | -11.97% |
| 2014 | $23.06B | $25.03B | +$1.97B | +8.55% |
| 2013 | $20.70B | $23.06B | +$2.36B | +11.42% |
| 2012 | $19.31B | $20.70B | +$1.39B | +7.18% |
| 2011 | $19.47B | $19.31B | −$155.00M | -0.80% |
| 2010 | $19.44B | $19.47B | +$29.00M | +0.15% |
| 2009 | $19.00B | $19.44B | +$436.00M | +2.29% |
| 2008 | $17.99B | $19.00B | +$1.01B | +5.62% |
| 2007 | $15.89B | $17.99B | +$2.10B | +13.24% |
| 2006 | $14.92B | $15.89B | +$962.00M | +6.45% |
| 2005 | $14.48B | $14.92B | +$444.00M | +3.07% |
| 2004 | $12.74B | $14.48B | +$1.74B | +13.66% |
| 2003 | $11.34B | $12.74B | +$1.40B | +12.35% |
| 2002 | $9.49B | $11.34B | +$1.85B | +19.49% |
| 2001 | $8.21B | $9.49B | +$1.28B | +15.63% |
| 2000 | $7.50B | $8.21B | +$712.00M | +9.50% |
| 1999 | $6.31B | $7.50B | +$1.18B | +18.72% |
| 1998 | $5.69B | $6.31B | +$624.00M | +10.97% |
| 1997 | $5.31B | $5.69B | +$377.00M | +7.10% |
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Quarter ended Jun 2026 | $9.13B | +8.7% | +4.3% |
| Quarter ended Mar 2026 | $8.40B | +10.5% | +4.1% |
| Quarter ended Dec 2025 | $7.60B | -14.3% | +32.5% |
| Quarter ended Sep 2025 | $8.87B | +1.4% | +24.6% |
| Quarter ended Jun 2025 | $8.75B | +8.5% | +3.7% |
| Quarter ended Mar 2025 | $8.07B | +40.7% | -0.2% |
| Quarter ended Dec 2024 | $5.74B | -19.5% | -11.1% |
| Quarter ended Sep 2024 | $7.12B | -15.6% | -11.2% |
| Quarter ended Jun 2024 | $8.44B | +4.3% | +1.8% |
| Quarter ended Mar 2024 | $8.09B | +25.4% | -0.5% |
| Quarter ended Dec 2023 | $6.45B | -19.6% | +13.6% |
| Quarter ended Oct 2023 | $8.03B | -3.2% | +9.2% |
| Quarter ended Jul 2023 | $8.29B | +2.0% | +0.9% |
| Quarter ended Apr 2023 | $8.13B | +43.1% | +3.0% |
| Quarter ended Dec 2022 | $5.68B | -22.8% | -10.1% |
| Quarter ended Oct 2022 | $7.35B | -10.6% | -15.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.